Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979864 | 0.78 | MAPT (0.32) | ALDH1A1CYP1A2POLB | |
| SCHEMBL2263851 | 0.77 | LMNA (0.35) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL4981731 | 0.72 | LMNA (0.36) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL21830589 | 0.64 | ALDH1A1 (0.52) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL401292 | 0.64 | LMNA (0.54) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL29467540 | 0.63 | ALDH1A1 (0.50) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL14782540 | 0.63 | LMNA (0.52) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL4853131 | 0.63 | ABL1 (0.36) | SMN1; SMN2ALDH1A1CYP1A2TDP1NPC1 | |
| SCHEMBL315179 | 0.62 | POLB (0.33) | KDM4EL3MBTL1CYP1A2TDP1POLB | |
| SCHEMBL9761009 | 0.62 | KDM4E (0.31) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5656648-A | TREATMENT OF PATHOLOGIES NECESSITATING STIMULATION OF CHOLECYSTOKININ-A RECEPTORS BY TOTAL OR PARTIAL AGONIST EFFECT | SANOFI (FR) | 1997-08-12 | — | — | US | claimed |
| CN-1107158-A | Polysubstituted 2-amino-thiazole derivatives | SANOFI ELF (FR) | 1995-08-23 | — | — | CN | claimed |
| EP-0611766-A1 | Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament | SANOFI (FR) | 1994-08-24 | — | — | EP | claimed |
| CN-101115764-B | New macrolides | BASILEA PHARMACEUTICA AG | 2012-09-26 | — | — | CN | disclosed |
| US-7524823-B2 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2009-04-28 | — | — | US | disclosed |
| EP-1846430-B1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| CN-101115764-A | New macrolides | BASILEA PHARMACEUTICA AG (CH) | 2008-01-30 | — | — | CN | disclosed |
| EP-1846430-A1 | NEW MACROLIDES | Basilea Pharmaceutica AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20060264387-A1 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2006-11-23 | — | — | US | disclosed |
| WO-2006084410-A1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| US-6380230-B1 | FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-04-30 | — | — | US | disclosed |
| EP-1017693-A1 | CARBOXAMIDOTHIAZOLE DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015525-A1 | CARBOXAMIDOTHIAZOLE DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 1999-04-01 | — | — | WO | disclosed |
| US-5656648-A | TREATMENT OF PATHOLOGIES NECESSITATING STIMULATION OF CHOLECYSTOKININ-A RECEPTORS BY TOTAL OR PARTIAL AGONIST EFFECT | SANOFI (FR) | 1997-08-12 | — | — | US | disclosed |
| US-5656648-A | TREATMENT OF PATHOLOGIES NECESSITATING STIMULATION OF CHOLECYSTOKININ-A RECEPTORS BY TOTAL OR PARTIAL AGONIST EFFECT | SANOFI (FR) | 1997-08-12 | — | — | US | disclosed |
| CN-1107158-A | Polysubstituted 2-amino-thiazole derivatives | SANOFI ELF (FR) | 1995-08-23 | — | — | CN | disclosed |
| EP-0611766-A1 | Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament | SANOFI (FR) | 1994-08-24 | — | — | EP | disclosed |
| EP-0611766-A1 | Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament | SANOFI (FR) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264387-A1 | Macrolides | PPME1, MGAM, SMPD1 | LMNA 2723/4885SMN1; SMN2 3789/4885ALDH1A1 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.